The EPO published patent application EP4048686A1 on March 25, 2026, covering a novel mini-insulin molecule with an extended C-terminal A chain developed by the University of Utah Research Foundation. The application is classified under IPC C07K 14/62 (insulin), A61K 38/28 (pharmaceutical preparations containing insulin), and A61P 3/10 (drugs for diabetes). Inventors are CHOU Danny Hung-Chieh and SAFAVI-HEMAMI Helena. The patent designates 35 European contracting states covering the major pharmaceutical markets.

Pharmaceutical and biotechnology companies developing insulin-based therapeutics should review this patent for potential freedom-to-operate implications. Parties interested in developing similar mini-insulin variants may need to seek licensing arrangements with the University of Utah Research Foundation. The patent provides 20-year exclusivity from the filing date across all designated European states.